Clinical Trial Update: Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on toxicity and pharmacokinetics of 2- and 3-weekly docetaxel in Metastatic Hormone-Sensitive Prostate Cancer. The study status is withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Peng Wang, MD PhD | Conditions: Metastatic Hormone-Sensitive Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN